Moderna Maintains Growth Forecast Despite Flu Vaccine Setback

Moderna has reported stronger-than-expected financial results for the fourth quarter of 2025, reinforcing its growth outlook for 2026 despite facing a significant setback concerning its flu vaccine candidate. The company announced its financial performance and growth projections on Friday, January 12, 2026, amid concerns following the U.S. Food and Drug Administration’s (FDA) decision to decline the review of its flu shot.

The Boston-based biotechnology firm recorded a revenue of $3.1 billion for the fourth quarter, exceeding analysts’ expectations. Moderna’s performance reflects strong demand for its COVID-19 vaccine, which continues to drive revenue as the pandemic persists. The company’s final figures for 2025 indicate a total revenue of $18 billion, demonstrating resilience in a competitive market.

Regulatory Challenges for Flu Vaccine Candidate

Despite its robust financial health, Moderna faced a setback when the FDA declined to review its flu vaccine candidate, which had been eagerly anticipated in the market. The decision, announced on January 5, 2026, raised concerns about the candidate’s regulatory pathway and future prospects. The exact reasons for the FDA’s decision have not been disclosed, leaving analysts and investors awaiting further clarification from the company.

In response to this regulatory hurdle, Moderna’s leadership reiterated its commitment to innovation and growth. The company remains focused on advancing its pipeline of vaccine candidates, which includes projects targeting various infectious diseases beyond COVID-19. Moderna’s Chief Executive Officer, Stéphane Bancel, expressed confidence in the company’s ability to navigate these challenges and continue its trajectory towards sustained growth.

2026 Growth Projections Remain Strong

Looking ahead, Moderna has reaffirmed its growth outlook for 2026, projecting revenues to reach approximately $23 billion. This forecast includes expectations for continued demand for its existing COVID-19 vaccines and potential contributions from its pipeline products. Analysts have noted that while the flu vaccine setback is concerning, the company’s diverse portfolio of mRNA-based products mitigates risk and positions it well for future success.

The company plans to provide additional updates on its flu vaccine candidate and other projects during its upcoming earnings call scheduled for March 15, 2026. Investors and industry analysts will be closely monitoring these developments, especially as Moderna continues to innovate in the field of vaccine technology.

Moderna’s reaffirmation of its growth outlook underscores the company’s resilience in the face of regulatory challenges. As it navigates this setback, its ability to maintain investor confidence will depend on its forthcoming strategies and the performance of its existing vaccine products.